Checkmate with Checkpoint Inhibitors: Hope and Hype

Jyoti Bajpai; Shubhada V Chiplunkar

doi:10.4103/ijmpo.ijmpo_103_19

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(02): 159-162
DOI: 10.4103/ijmpo.ijmpo_103_19

Editorial

Checkmate with Checkpoint Inhibitors: Hope and Hype

Authors

Jyoti Bajpai

Department of Medical Oncology, Tata Memorial Centre, Tata Memorial Hospital, Mumbai
Shubhada V Chiplunkar

Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, Maharashtra, India

Abstract

Volltext

Referenzen

References
1 Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018; 8: 1069-86
2 Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf 2013; 12: 631-45
3 Chiriva-Internati M, Bot A. A new era in cancer immunotherapy: Discovering novel targets and reprogramming the immune system. Int Rev Immunol 2015; 34: 101-3
4 Yang Y. Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest 2015; 125: 3335-7
5 Pardoll D. Cancer and the immune system: Basic concepts and targets for intervention. Semin Oncol 2015; 42: 523-38
6 Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. et al. Current challenges in cancer treatment. Clin Ther 2016; 38: 1551-66
7 Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. A personalized view on cancer immunotherapy. Cancer Lett 2014; 352: 113-25
8 Adams KT. Cancer immunotherapies – And their cost – Take center stage at ASCO's 2015 annual meeting. Manag Care 2015; 24: 30-2
9 Tartari F, Santoni M, Burattini L, Mazzanti P, Onofri A, Berardi R. et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. Cancer Treat Rev 2016; 48: 20-4
10 Grady D. Harnessing the Immune System to Fight Cancer. The New York Times; 30 July, 2016. Available from: http://www.nytimes.com/2016/07/31/health/harnessing-the-immune-system-to-fightcancer.html. [Last accessed on 2016 Aug 17]
11 National Cancer Institute. Checking in on Cancer Checkpoint Inhibitors. National Cancer Institute; 18 December, 2015. Available from: http://www.cancer.gov/newsevents/cancer-currents-blog/2015/gulley-checkpoint. [Last accessed on 2016 Oct 26]
12 Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53: 27-42
13 Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system?. Semin Immunol 1996; 8: 271-80
14 Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future. J Clin Invest 2015; 125: 3384-91
15 Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T. et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107: 7875-80
16 Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26: 923-37
17 Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C. et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest 2015; 125: 2046-58
18 Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-8
19 Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-99
20 Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G. et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: A Rationale for personalized immunotherapy. Cancer Res 2015; 75: 3446-55
21 Voss MH, Hellmann MD, Chen Y, Gold TM, Lambert CR, VanAllen E. et al. Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab. J Clin Oncol 2016; 34 (02) 514
22 Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS. et al. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV – Counterparts that has implications for immunotherapy. Oncoimmunology 2018; 7: e1498439
23 Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24: 541-50
24 Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 2018; 6: 157
25 Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-62
26 Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71
27 Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V. et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: A multicentre, retrospective analysis. Lancet Respir Med 2018; 6: 771-81
28 Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359: 97-103
29 Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018; 359: 104-8
30 Fuentes-Antrás J, Provencio M, Díaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev 2018; 70: 16-21
31 Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 2018; 58: 125-35
32 I-OSI | Home Available from: http://www.immunooncologyindia.com/. [Last accessed on 2019 Apr]